Cancer clinical trials in the region Occitanie
385 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06128551
Phase 1b Escalade de dose
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT04585750
#2023-504251-27-00
Phase 2 autres tumeurs solides
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
#NCT06772623
#2024-514465-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
7 recruiting sites
Abbvie
Phase 1 / Phase 2
Breast cancer
#NCT06827236
#2024-517979-20-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT06564038
#2024-515034-33-00
Cohorte 1A et 1C
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohortes 3A et 3B Lymphome à grandes cellules B
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
None
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohorte 3A Lymphomes B non hodgkinien R/R
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
MALT lymphoma
Lymphocytic lymphoma
Indolent transformed lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT06564038
#2024-515034-33-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohorte 2A et 2C
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05181735
#2021-000596-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
EPO / Growth factors
Required IPSS-R prognostic scores
Low
Intermediate
Required IPSS-M prognostic scores
Low
Moderately low
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
27 recruiting sites
Groupe Francophone des Myélodysplasies